Back to Challenges
BIOTECHNOLOGY
under_review
AI GeneratedBiotech Patent Monopolism: Only 5% of mRNA Capacity in LMICs While 25% of Disease Burden Is There
Problem Definition
Patent systems and IP enforcement prevent developing nations from manufacturing essential medicines and vaccines. mRNA vaccine manufacturing concentrated in 3 countries; African continent has <2% capacity despite bearing 25% of global disease burden. Patent monopolies extend exclusivity 15+ years beyond R&D costs, locking out competitors and manufacturing capability.
Root Causes
TRIPS agreement and strong IP enforcement in most trade agreements
Capital requirements for biotech manufacturing prevent new entrants in developing nations
Technology transfer locked behind licensing negotiations with incumbent firms
Minimal incentive for voluntary licensing to low-margin markets (Africa, South Asia)
Scope
Share
Priority
Evaluation Scores
Complexity8.0
Priority9.0
Interconnected8.0
Risk Level9.0
Clarity9.0
Composite Score
8.6
Metadata
Linked Ideas:No ideas yet
Evaluations:2
Version:1